292 related articles for article (PubMed ID: 16816380)
1. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
2. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
3. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of EphB4 in mesothelioma and its biological significance.
Xia G; Kumar SR; Masood R; Koss M; Templeman C; Quinn D; Zhu S; Reddy R; Krasnoperov V; Gill PS
Clin Cancer Res; 2005 Jun; 11(12):4305-15. PubMed ID: 15958611
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
7. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.
Xia G; Kumar SR; Stein JP; Singh J; Krasnoperov V; Zhu S; Hassanieh L; Smith DL; Buscarini M; Broek D; Quinn DI; Weaver FA; Gill PS
Oncogene; 2006 Feb; 25(5):769-80. PubMed ID: 16205642
[TBL] [Abstract][Full Text] [Related]
8. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
Kumar SR; Masood R; Spannuth WA; Singh J; Scehnet J; Kleiber G; Jennings N; Deavers M; Krasnoperov V; Dubeau L; Weaver FA; Sood AK; Gill PS
Br J Cancer; 2007 Apr; 96(7):1083-91. PubMed ID: 17353927
[TBL] [Abstract][Full Text] [Related]
9. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
Magic Z; Sandström J; Perez-Tenorio G
Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
[TBL] [Abstract][Full Text] [Related]
10. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
11. Low concentrations of TNF-α promote osteogenic differentiation via activation of the ephrinB2-EphB4 signalling pathway.
Wang L; Zhang J; Wang C; Qi Y; Du M; Liu W; Yang C; Yang P
Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27726217
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
13. Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Kawahara Y; Furuta T; Sabit H; Tamai S; Dong Y; Jiapaer S; Zhang J; Zhang G; Oishi M; Miyashita K; Hayashi Y; Nakada M
Cancer Lett; 2019 May; 449():56-65. PubMed ID: 30776480
[TBL] [Abstract][Full Text] [Related]
14. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
15. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Huang X; Yamada Y; Kidoya H; Naito H; Nagahama Y; Kong L; Katoh SY; Li WL; Ueno M; Takakura N
Cancer Res; 2007 Oct; 67(20):9800-8. PubMed ID: 17942910
[TBL] [Abstract][Full Text] [Related]
16. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
17. EphB4 expression and biological significance in prostate cancer.
Xia G; Kumar SR; Masood R; Zhu S; Reddy R; Krasnoperov V; Quinn DI; Henshall SM; Sutherland RL; Pinski JK; Daneshmand S; Buscarini M; Stein JP; Zhong C; Broek D; Roy-Burman P; Gill PS
Cancer Res; 2005 Jun; 65(11):4623-32. PubMed ID: 15930280
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Gynecol Oncol; 2009 Jul; 114(1):84-8. PubMed ID: 19356789
[TBL] [Abstract][Full Text] [Related]
19. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
20. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL).
Rychahou PG; Murillo CA; Evers BM
Surgery; 2005 Aug; 138(2):391-7. PubMed ID: 16153452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]